Barclays PLC Has $325,000 Stake in MacroGenics, Inc. (NASDAQ:MGNX)

Barclays PLC boosted its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 97.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,753 shares of the biopharmaceutical company’s stock after buying an additional 48,639 shares during the period. Barclays PLC owned about 0.16% of MacroGenics worth $325,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of MacroGenics during the 3rd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. boosted its holdings in MacroGenics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,707 shares in the last quarter. DRW Securities LLC bought a new stake in shares of MacroGenics in the 2nd quarter valued at approximately $56,000. K2 Principal Fund L.P. acquired a new position in shares of MacroGenics in the 2nd quarter worth approximately $63,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in MacroGenics by 300.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,072 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 12,060 shares in the last quarter. Institutional investors own 96.89% of the company’s stock.

MacroGenics Trading Up 4.8 %

Shares of NASDAQ:MGNX opened at $3.46 on Friday. MacroGenics, Inc. has a 1-year low of $2.95 and a 1-year high of $21.88. The stock has a market capitalization of $217.16 million, a P/E ratio of -2.19 and a beta of 2.04. The business has a 50-day moving average price of $3.51 and a two-hundred day moving average price of $3.76.

Analyst Upgrades and Downgrades

MGNX has been the subject of several recent analyst reports. JMP Securities lowered MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. Evercore ISI raised shares of MacroGenics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.63.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.